CDTX SEC Filings - Cidara Theraptcs 10-K, 10-Q, 8-K Forms
This page provides a comprehensive resource for Cidara Therapeutics (CDTX) SEC filings, including annual, quarterly, and material event reports, as well as insider trading forms. It highlights key events such as the company's acquisition by Merck, clinical development plans for CD388, and financing activities. The platform also offers AI-powered summaries of these regulatory documents for easier investor analysis.
Merck Completes Tender Offer and Moves to Acquire Cidara Therapeutics
Merck has completed its tender offer to acquire Cidara Therapeutics by purchasing approximately 85.96% of Cidara's outstanding stock at $221.50 per share. Merck plans to finalize the acquisition through a merger, making Cidara a wholly owned subsidiary and delisting its shares from Nasdaq. This acquisition aims to strengthen Merck's respiratory portfolio, particularly with Cidara's investigational antiviral CD388, and is expected to impact Merck's 2026 R&D expenses and earnings per share.
Merck & Co., Inc., Rahway, N.J., USA Announces Fourth-Quarter and Full-Year 2025 Financial Results; Highlights Progress Advancing Broad, Diverse Pipeline
Merck & Co. announced strong fourth-quarter and full-year 2025 financial results, with worldwide sales reaching $16.4 billion and $65.0 billion respectively, driven by robust performance in Oncology and Animal Health, and increasing contributions from WINREVAIR and CAPVAXIVE. The company also highlighted significant pipeline advancements, including positive late-stage trial results for 18 Phase 3 trials and strategic acquisitions that augmented its portfolio. Merck further detailed its 2026 financial outlook, anticipating worldwide sales between $65.5 billion and $67.0 billion and non-GAAP EPS between $5.00 and $5.15.
RedChip Companies Congratulates Former Client Cidara Therapeutics on Its $9.2 Billion Acquisition by Merck
RedChip Companies congratulated its former client, Cidara Therapeutics, on its acquisition by Merck for approximately $9.2 billion. RedChip had introduced Cidara to its investor network in 2021 when its market capitalization was under $100 million. The acquisition highlights Cidara's CD388, an investigational antiviral in Phase 3 development for influenza prevention.
RedChip Companies Congratulates Former Client Cidara Therapeutics on Its $9.2 Billion Acquisition by Merck
RedChip Companies congratulated its former client, Cidara Therapeutics, on its approximately $9.2 billion acquisition by Merck. RedChip had introduced Cidara to its investor network in 2021 when the company was valued under $100 million. The acquisition highlights Cidara’s innovative Cloudbreak® platform and its lead compound CD388, an investigational long-acting antiviral in Phase 3 development for influenza prevention.
Cidara Therapeutics (NASDAQ:CDTX) Upgraded at Wall Street Zen
Wall Street Zen has upgraded Cidara Therapeutics (NASDAQ:CDTX) to a "sell" rating, despite some other analysts maintaining "buy" or "hold" ratings, leading to a mixed sentiment and an average target price of $156.11. The company recently missed its quarterly EPS estimates, and its COO sold a significant portion of his shares. Cidara Therapeutics is a clinical-stage biotechnology company focused on anti-infectives and immunotherapies, with its lead asset rezafungin in late-stage development.
Cidara Therapeutics (NASDAQ: CDTX) bought by Merck, shares delist
Cidara Therapeutics has completed its acquisition by Merck Sharp & Dohme LLC, ceasing to be a publicly traded company. Merck's subsidiary acquired Cidara shares for $221.50 per common share and $15,505.00 per Series A preferred share in cash, resulting in the delisting of CDTX from Nasdaq and the termination of Cidara's public reporting obligations. The transaction was finalized on January 7, 2026, with Merck designees taking over governance.
Merck completes Cidara Therapeutics (CDTX) merger; director options cashed
Merck completed its acquisition of Cidara Therapeutics (CDTX) on January 7, 2026, merging its subsidiary into Cidara. In connection with the merger, all outstanding Cidara stock options, including those held by director Joshua Resnick, were fully vested and converted into cash rights based on an excess of $221.50 per share over the exercise price. Resnick's options, covering 22,200 and 5,079 shares, were cashed out, though he disclaims beneficial ownership as they are held for the benefit of RA Capital Healthcare Fund.
Cidara Therapeutics, Inc. (NASDAQ:CDTX) Receives Consensus Recommendation of "Hold" from Analysts
Cidara Therapeutics, Inc. (CDTX) has received a consensus "Hold" recommendation from twelve brokerages, with an average 12-month price target of $156.11. Insider transactions show COO Shane Ward selling a significant portion of his shares, while institutional investors have adjusted their positions. The company, which is developing the antifungal drug rezafungin, reported a quarterly EPS miss and currently trades with a market cap of $6.96 billion.
Cidara Therapeutics Completes Acquisition and Becomes Private Company
Cidara Therapeutics has completed its acquisition, transitioning into a private company following a cash tender offer for approximately 88.3% of its voting shares. All remaining public shares and equity instruments were converted to cash or canceled, its Nasdaq listing was halted, and corporate governance was replaced. Despite significant financial challenges, strong technical momentum and strategic corporate events, including a merger with Merck, suggest potential future growth for the company, according to Spark, TipRanks' AI Analyst.
Merck Acquires Cidara Therapeutics
Merck has successfully completed its acquisition of Cidara Therapeutics through a cash tender offer. This acquisition strengthens Merck's respiratory portfolio, particularly with Cidara's investigational drug CD388, a long-acting antiviral for influenza prevention. The deal involved a purchase price of $221.50 per share, making Cidara a wholly owned subsidiary of Merck.
RedChip Companies Congratulates Former Client Cidara Therapeutics on Its $9.2 Billion Acquisition by Merck
RedChip Companies congratulated its former client, Cidara Therapeutics, on being acquired by Merck for approximately $9.2 billion. RedChip had introduced Cidara to its investor network in 2021 when its market capitalization was under $100 million. The acquisition highlights Cidara's investigational long-acting antiviral, CD388, which is in Phase 3 development and has received Breakthrough Therapy Designation from the FDA.
Cidara therapeutics CEO Stein buys shares for $339k
Cidara Therapeutics CEO Jeffrey Stein acquired shares worth $339,039 in multiple transactions between 2017 and 2020 through a trust. The stock has seen a significant return of 790% over the past year, with the 2020 purchase being particularly well-timed as the stock nears its 52-week high. Merck recently announced its intent to acquire Cidara Therapeutics for approximately $9.2 billion, which has led to analyst downgrades and price target adjustments to align with the acquisition price.
Cidara Therapeutics Announced Transfer or Voluntary Withdrawal of Listing
Cidara Therapeutics (CDTX) announced its merger closure on January 7, 2026, leading to a trading halt and delisting request from Nasdaq for its common shares. The company intends to file a Form 15 to terminate registration and suspend its SEC reporting obligations, as per an SEC filing.
Cidara Therapeutics Announces Board and Management Changes
Cidara Therapeutics, Inc. announced significant board and management changes on January 7, 2026, following a merger. Several directors resigned, and new directors and officers were appointed, including Jon Filderman, Melissa Leonard, and Dalton Smart. These changes are a result of the merger agreement, as detailed in their SEC 8-K filing.
Merck completes acquisition of Cidara Therapeutics
Merck has successfully completed its acquisition of Cidara Therapeutics through a cash tender offer at $221.50 per share. Cidara will become a wholly-owned subsidiary of Merck, and its common stock will no longer be listed on the Nasdaq Global Market. This acquisition strengthens Merck's respiratory portfolio, particularly with Cidara's long-acting antiviral candidate, CD388, for influenza prevention, and is expected to result in a $9.0 billion charge to Merck's 2026 research and development expenses.
CDTX Stock Price, Forecast & Analysis | CIDARA THERAPEUTICS INC (NASDAQ:CDTX)
This article provides an analysis of CIDARA THERAPEUTICS INC (NASDAQ:CDTX) stock, including its current price, key statistics, and performance. It details the company's profile, its Cloudbreak platform for developing immunotherapies, and analyst forecasts predicting a slight price decrease but significant EPS growth for the next year.
Stock Watch: Biotech Acquisitions Drive Sector Momentum Going Into 2026
Biotech acquisitions are driving significant momentum in the life science sector as the industry moves into 2026. This article provides an investor's perspective on biopharma business trends, highlighting the impact of year-end portfolio reviews and major company activities. The analysis focuses on how these strategic moves are shaping the future landscape for various pharmaceutical and biotech firms.
RedChip Companies Congratulates Former Client Cidara Therapeutics on Its $9.2 Billion Acquisition by Merck
RedChip Companies, an investor relations firm, congratulated its former client Cidara Therapeutics on its $9.2 billion acquisition by Merck. RedChip had introduced Cidara to investors when its market capitalization was under $100 million, highlighting its groundbreaking antiviral and antifungal programs, which culminated in this significant acquisition. The acquisition centers on CD388, Cidara’s investigational long-acting antiviral for influenza prevention, which is now in Phase 3 development and has received FDA Breakthrough Therapy Designation.
Cidara Therapeutics stock hits 52-week high at 221.24 USD
Cidara Therapeutics stock reached a 52-week high of $221.24, reflecting a significant 730.32% growth over the past year. This surge is attributed to positive pipeline developments and strategic partnerships, including a recent acquisition offer from Merck for $221.50 per share. Despite the company being unprofitable as indicated by a P/E ratio of -19.87, investor confidence remains high.
Cidara Therapeutics stock hits 52-week high at 221.24 USD By Investing.com
Cidara Therapeutics (CDTX) stock has reached a 52-week high of $221.24, reflecting a 730.32% return over the past year. This surge is fueled by pipeline developments and an acquisition offer from Merck for $221.50 per share, though analysts have downgraded the stock following this news, citing the limited remaining upside. The company reported $476 million in cash for Q3 2025 but no revenue.
Cidara Therapeutics (CDTX) Rockets 722% in 2025 on Merck $9.2-Billion Merger
Cidara Therapeutics Inc. quadrupled in 2025 due to a $9.2-billion merger with Merck, announced in November, valuing its shares at $221.50 apiece. The acquisition was spurred by Cidara receiving fast-track FDA designation for its influenza prevention drug candidate, CD388, currently in Phase 3 trials. The merger is anticipated to finalize in the first quarter of 2026, pending regulatory and shareholder approvals.
RedChip Companies Congratulates Former Client Cidara Therapeutics on Its $9.2 Billion Acquisition by Merck
RedChip Companies, an investor relations firm, congratulated its former client, Cidara Therapeutics, on its $9.2 billion acquisition by Merck. RedChip had introduced Cidara to investors in 2021 when its market capitalization was under $100 million, highlighting its antiviral and antifungal programs. The acquisition focuses on CD388, Cidara's investigational long-acting antiviral for influenza prevention, which is in Phase 3 development and has Breakthrough Therapy Designation from the FDA.
Merck, Cidara Therapeutics granted early termination by US FTC
Merck and Cidara Therapeutics, Inc. have been granted early termination by the US Federal Trade Commission (FTC) for Merck's proposed $9.2 billion acquisition of Cidara. The early termination was granted on December 19, 2025, and the deal is expected to close in the first quarter of 2026.
RedChip Companies Congratulates Former Client Cidara Therapeutics on Its $9.2 Billion Acquisition by Merck
RedChip Companies congratulates its former client, Cidara Therapeutics, on being acquired by Merck for approximately $9.2 billion. RedChip had introduced Cidara to investors in 2021 when its market capitalization was under $100 million, highlighting its innovative Cloudbreak® platform and long-acting antiviral programs. This acquisition validates both Cidara's vision and RedChip's mission of spotlighting promising small-cap opportunities for investors.
Cidara Therapeutics (CDTX): Assessing Valuation After a 200% Three‑Month Share Price Surge
Cidara Therapeutics (CDTX) has seen a dramatic 200%+ share price surge over the past three months and an 879% year-over-year return, prompting an evaluation of its current valuation. While its price-to-book ratio of 16.4x suggests overvaluation compared to peers, a Discounted Cash Flow (DCF) model estimates a fair value of $407.65 per share, indicating significant undervaluation despite the recent growth. The company remains loss-making and reliant on successful trial outcomes, posing risks to its momentum.
Cidara Therapeutics (CDTX): Assessing Valuation After a 239% Three‑Month and 864% One‑Year Share Price Surge
Cidara Therapeutics (CDTX) has seen substantial share price gains, up 239% in three months and 864% over one year, despite ongoing losses. While its price-to-book ratio suggests an aggressive valuation compared to the biotech industry average, a Discounted Cash Flow (DCF) model from Simply Wall St indicates the shares might be trading at a significant discount to their estimated fair value. This discrepancy prompts a closer look at whether the market has accurately priced in Cidara's future growth potential or if it remains undervalued.
RedChip Companies Congratulates Former Client Cidara Therapeutics on Its $9.2 Billion Acquisition by Merck
RedChip Companies congratulated its former client, Cidara Therapeutics, on its $9.2 billion acquisition by Merck, highlighting the journey of Cidara from a sub-$100 million market capitalization to a key strategic acquisition. RedChip, an investor relations firm, had introduced Cidara to its investor network in 2021, recognizing the potential of its antiviral and antifungal programs, including CD388 which is now in Phase 3 development for influenza prevention. This acquisition validates Cidara's vision and RedChip's mission to identify promising small-cap opportunities for investors.
Cidara Therapeutics, Inc. $CDTX Shares Sold by BVF Inc. IL
BVF Inc. IL decreased its holdings in Cidara Therapeutics (NASDAQ:CDTX) by 15.0%, selling 138,250 shares and retaining 786,392 shares worth approximately $38.3 million. Concurrently, Bain Capital Life Sciences Investors LLC significantly increased its stake by 255.7% to over 2.5 million shares, valued at $121.8 million. Overall, hedge funds and institutional investors now own about 35.82% of Cidara Therapeutics, which has a consensus analyst rating of "Hold" and a price target of $156.11.
Shane Ward Sells 9,959 Shares of Cidara Therapeutics (NASDAQ:CDTX) Stock
Shane Ward, COO of Cidara Therapeutics (NASDAQ:CDTX), sold 9,959 shares of the company's stock on December 10th for approximately $2.19 million, reducing his holding by 28.46%. The company's stock is trading near its 52-week high, despite a negative P/E ratio, while institutional investors show mixed sentiment with some significantly increasing their stakes. Analysts currently have a "Hold" consensus rating for CDTX.
Cidara Therapeutics, Inc. (NASDAQ:CDTX) Receives Average Rating of "Hold" from Brokerages
Cidara Therapeutics, Inc. (NASDAQ:CDTX) has received an average "Hold" rating from twelve research firms, with an average one-year price target of $156.11, despite the stock trading significantly higher at around $220.65. Recent insider activity shows COO Shane Ward selling shares, reducing his stake by over 28%, and the company missed Q3 EPS estimates, reporting a loss of ($1.43) against an expected ($1.19). Institutional investors have recently modified their holdings in CDTX, with hedge funds and institutional investors owning 35.82% of the stock.
Cidara therapeutics COO Ward sells $2.19 million in stock By Investing.com
Shane Ward, COO & Chief Legal Officer of Cidara Therapeutics (NASDAQ:CDTX), sold 9,959 shares for $2.19 million and disposed of 15,041 shares to cover taxes on RSU vesting. These transactions followed Merck's announcement to acquire Cidara Therapeutics for $221.50 per share, valuing the deal at $9.2 billion, prompting several firms to downgrade Cidara's stock.
CEO Stein Surrenders 2,285 Of Cidara Therapeutics Inc [CDTX]
Jeffrey Stein, CEO of Cidara Therapeutics Inc (CDTX), filed a Form 4 disclosing the surrender of 2,285 shares back to the company on December 10, 2025. This transaction was valued at $501,786, with shares priced at $219.60, and was done to cover option exercise costs and/or tax liabilities. Stein's ending holdings in the company are 82,879 shares.
Cidara therapeutics COO Ward sells $2.19 million in stock
Shane Ward, COO & Chief Legal Officer of Cidara Therapeutics, Inc., sold 9,959 shares of common stock for $2,191,746 and disposed of another 15,041 shares to cover taxes on RSU vesting. Concurrently, Ward acquired 9,959 shares through option exercises for $188,760. These transactions follow Merck's announcement to acquire Cidara Therapeutics for $221.50 per share, leading to analyst downgrades despite the company's strong cash position and progress with its lead candidate, CD388.
Cidara Therapeutics’ Earnings Call Highlights CD388 Progress
The article reports that Cidara Therapeutics' recent earnings call focused on the progress of their drug candidate, CD388. This indicates the company is prioritizing the development and potential of CD388, likely sharing updates on clinical trials or regulatory milestones with investors.
BRODSKY & SMITH SHAREHOLDER UPDATE: Notifying Investors of the Following Investigations: Mersana Therapeutics, Inc. (Nasdaq - MRSN), Cidara Therapeutics, Inc. (Nasdaq - CDTX), Cadence Bank (NYSE – CADE)
Brodsky & Smith, a litigation law firm, has initiated investigations into three companies: Mersana Therapeutics, Inc. (MRSN), Cidara Therapeutics, Inc. (CDTX), and Cadence Bank (CADE). These investigations concern potential breaches of fiduciary duties by the Boards of Directors in their respective acquisition processes, focusing on whether the deal considerations provide fair value to the shareholders. Investors are encouraged to contact the firm if they own shares in any of these companies.
BRODSKY & SMITH SHAREHOLDER UPDATE: Notifying Investors of the Following Investigations: Mersana Therapeutics, Inc. (Nasdaq - MRSN), Cidara Therapeutics, Inc. (Nasdaq - CDTX), Cadence Bank (NYSE – CADE)
Brodsky & Smith is notifying investors about ongoing investigations concerning the proposed acquisitions of Mersana Therapeutics, Inc. (MRSN), Cidara Therapeutics, Inc. (CDTX), and Cadence Bank (CADE). The investigations aim to determine if the respective company Boards breached their fiduciary duties to shareholders by failing to secure fair value in these acquisition deals. Shareholders are encouraged to contact Brodsky & Smith for discussions regarding these investigations.
RedChip Companies Congratulates Former Client Cidara Therapeutics on Its $9.2 Billion Acquisition by Merck
RedChip Companies, a leader in investor relations for microcap and small-cap companies, congratulated its former client, Cidara Therapeutics, on its $9.2 billion acquisition by Merck. RedChip had introduced Cidara to its investor network in 2021 when its market capitalization was under $100 million, highlighting its vision and the importance of early investment in promising small-cap opportunities. The acquisition focuses on Cidara’s investigational long-acting antiviral, CD388, which is in Phase 3 development and was granted Breakthrough Therapy Designation by the FDA.
RedChip Companies Congratulates Former Client Cidara Therapeutics on Its $9.2 Billion Acquisition by Merck
RedChip Companies congratulated its former client, Cidara Therapeutics, on its acquisition by Merck for approximately $9.2 billion. RedChip had introduced Cidara to its investor network in 2021 when its market capitalization was under $100 million, highlighting the company's progress from an emerging growth story to a major acquisition. The acquisition is centered on CD388, Cidara's investigational long-acting antiviral in Phase 3 development for preventing influenza.
Cidara Therapeutics stock hits 52-week high at 220.49 USD
Cidara Therapeutics Inc. (CDTX) stock has reached a new 52-week high of $220.49, reflecting a 1-year total return of 1141.61%. This surge follows Merck's announced intention to acquire Cidara for $221.50 per share, valuing the company at approximately $9.2 billion, driven by its lead candidate CD388. Despite the positive market sentiment and valuation, InvestingPro data suggests the stock is significantly overvalued with high price volatility, leading analysts to downgrade ratings to Neutral or Equalweight, aligning price targets with the acquisition offer.
Merck to acquire Cidara Therapeutics for $9.2B
Merck & Co Inc has announced its agreement to acquire Cidara Therapeutics Inc in a $9.2 billion cash deal, paying $221.50 per share, which is more than double Cidara’s stock price before the announcement. This acquisition is focused on Cidara's lead candidate, CD388, a long-acting antiviral drug designed to prevent influenza, and aligns with Merck's strategy to diversify its drug portfolio as its blockbuster cancer therapy, Keytruda, approaches patent expiration in 2028. The transaction, pending regulatory approvals, is expected to finalize in the first quarter of 2026.
Cidara Therapeutics Reaches Target Enrollment of Phase 3 ANCHOR Trial Evaluating CD388 for Prevention of Seasonal Influenza in High-Risk Populations
Cidara Therapeutics announced it has reached target enrollment of 6,000 participants for its Phase 3 ANCHOR trial evaluating CD388, a non-vaccine preventative for seasonal influenza in high-risk populations. This milestone was achieved ahead of the Northern Hemisphere's peak flu season. An interim analysis is planned for Q1 2026 to determine if additional enrollment is needed during the Southern Hemisphere flu season, with successful results from this single Phase 3 trial potentially sufficient for BLA approval.
Cidara Therapeutics Reaches Target Enrollment of Phase 3
Cidara Therapeutics, Inc. has achieved target enrollment of 6,000 participants in its Phase 3 ANCHOR trial for CD388, a non-vaccine preventative for seasonal influenza. The trial evaluates CD388's safety and efficacy in high-risk populations, with an interim analysis planned for Q1 2026. This milestone is a crucial step towards potential BLA approval for CD388.
Merck Is Buying Cidara Therapeutics for $9.2 Billion. Is This the Boost the Lagging Drugmaker Needs?
Merck is acquiring clinical-stage biotech Cidara Therapeutics for $9.2 billion to gain access to CD388, a promising long-acting antiviral drug for the flu. This acquisition aims to address challenges Merck faces, including decreased demand for its HPV vaccine and the upcoming patent cliff for Keytruda. The move could diversify Merck's product lineup and strengthen its position in the pharmaceutical market.
Cidara (CDTX) Climbs 105% on $9.2-Billion Merger with Merck
Cidara Therapeutics Inc. (NASDAQ:CDTX) saw its stock price climb significantly by over 105% following the announcement of its acquisition by Merck Co. for $9.2 billion. The agreement values Cidara shares at $221.50 apiece, with the transaction expected to close in the first quarter of 2026. This acquisition comes after Cidara received a fast track designation from the FDA for its influenza drug candidate, CD388, which is currently in Phase 3 trials.
Cidara Therapeutics (CDTX) Skyrockets 105% on Merck $9.2-Billion Acquisition Bid
Cidara Therapeutics (CDTX) shares surged over 105% after the company announced an agreement to be acquired by pharmaceutical giant Merck for $9.2 billion. The acquisition, expected to close in Q1 2026, follows Cidara receiving a fast-track FDA designation for its influenza prevention drug candidate, CD388.
Cidara Therapeutics Shares Soar 105% After Merck Agrees To $9.2B Takeover Deal
Cidara Therapeutics (CDTX) shares surged over 105% after Merck & Co. announced an agreement to acquire all outstanding shares for $221.50 per share in cash, valuing the transaction at approximately $9.2 billion. This acquisition aligns with Merck's strategy to strengthen its pipeline with late-stage assets and reduce its reliance on its primary drug, which faces upcoming patent challenges. The announcement led to unusually high trading volume for CDTX.
This is why Merck is buying a flu biotech for $9.2 billion and Wall Street is happy
Merck & Co. is acquiring an experimental antiviral drug developer for $9.2 billion to address upcoming patent expirations for its key drugs, Keytruda and Gardasil. This acquisition aligns with Merck's strategy to invest in late-stage assets to sustain revenue growth. The move is seen as a way to mitigate the impact of Keytruda losing patent protection in 2028, a drug that generated $29.5 billion in revenue in 2024.
Merck stakes $9.2B on Cidara and its long-acting flu drug
Merck & Co. has agreed to acquire Cidara Therapeutics for $9.2 billion to gain rights to CD388, a long-acting preventive flu medicine. This deal, one of Merck's two multibillion-dollar buyouts this year, aims to secure a potential top-selling drug that could serve as an alternative to flu vaccines. CD388 is currently in late-stage testing and has a fast-track FDA designation, with analysts projecting a $3.8 billion market opportunity, which would help Merck offset revenue loss from its expiring Keytruda patent.
Merck to Buy Cidara Therapeutics in $9.2 Billion Deal - WSJ
Merck & Co. has announced a $9.2 billion deal to acquire biotechnology company Cidara Therapeutics. This acquisition significantly strengthens Merck's respiratory product portfolio and pipeline. The move comes as Merck prepares for the eventual loss of patent exclusivity for its major cancer drug, Keytruda, aiming to secure future growth.
